Skip to main content

Phathom Pharmaceuticals, Inc.

corporate_fare Company Profile

Phathom Pharmaceuticals, Inc.

PHAT·NASDAQ·Life Sciences·CIK 0001783183

We are a commercial-stage biopharmaceutical company focused on commercializing and developing new treatments for gastrointestinal (GI) diseases. Our approved products, VOQUEZNA®, VOQUEZNA® DUAL PAK®, and VOQUEZNA® TRIPLE PAK®, contain vonoprazan. Vonoprazan is an oral small molecule potassium-competitive acid blocker (PCAB), a class of molecules that block acid secretion in the stomach. VOQUEZNA is the only PCAB approved for marketing and sale in the United States. We began U.S. commercialization of VOQUEZNA for erosive gastroesophageal reflux disease (Erosive GERD) and Helicobacter pylori (H. pylori) infection, and VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK for H. pylori infection, in November 2023. The U.S. Food and Drug Administration (FDA) approved VOQUEZNA for heartburn associated with Non-Erosive GERD in July 2024. Vonoprazan was originally developed by Takeda Pharmaceutical Company Limited and is marketed in multiple countries outside the United States. We licensed U.S., European, and Canadian rights to vonoprazan from Takeda in 2019. We independently commercialize VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK in the United States. For the year ended December 31, 2025, we generated increased revenues from sales of our VOQUEZNA products compared to the prior year, with the majority of 2025 revenue from VOQUEZNA sales. During this period, we saw growth in prescription volume and prescriber adoption, with most prescriptions for GERD indications. As of February 13, 2026, over 1.1 million prescriptions for our VOQUEZNA products have been filled since launch. We have broad commercial coverage for VOQUEZNA, with access for over 120 million, or over 80%, of U.S. commercial lives.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for PHAT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Major Investor Frazier Life Sciences Files to Liquidate Entire 8.2% Stake Near 52-Week Highs

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$175.11M
Net Income
-$221.25M
Diluted EPS
-$3.03
Op. Cash Flow
-$166.78M
Free Cash Flow
-$167M
Gross Profit
$152.51M
Operating Income
-$159.99M
Cash & Equivalents
$129.97M
Total Debt
$209.09M
Debt / Equity
-0.48×
Net Margin
-126.3%
Shares Outstanding
71.42M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-073379
$4.66
52-week range · as of 2026-10-29 $4.66 – $18.31
Market cap
$378.82M
Volume
1.3M (0.8× avg)
3-mo avg 1.7M
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PHAT - Filings & News (Page 2)

PHAT
Jan 07, 2026, 4:01 PM EST
Filing Type: S-3ASR
Importance Score:
8
Price at Filing: $18.16
Real-time Price: $4.66 info
Change: -$13.50 (-74%) info
Market Cap: $378.819M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets